Large-scale Direct Targeting for Drug Repositioning and Discovery

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Zheng, Chunli ^a   Guo, Zihu ^a   Huang, Chao ^a   Wu, Ziyin ^a   Li, Yan ^b   Chen, Xuetong ^a   Fu, Yingxue ^a   Ru, Jinlong ^a   Ali Shar, Piar ^a   Wang, Yuan ^c   Wang, Yonghua ^a  

^a NORTHWEST A F UNIVERSITY   (China)

^b DALIAN UNIVERSITY OF TECHNOLOGY   (China)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND;

ALGORITHM; BIOLOGY; DRUG DEVELOPMENT; DRUG REPOSITIONING; PROCEDURES; REPRODUCIBILITY; WEB BROWSER;

ALGORITHMS; COMPUTATIONAL BIOLOGY; DRUG DISCOVERY; DRUG REPOSITIONING; LIGANDS; REPRODUCIBILITY OF RESULTS; WEB BROWSER;

EID: 84936972913     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep11970     Document Type: Article

References (21)

1. Günther, S. et al. SuperTarget and Matador: resources for exploring drug-target relationships. Nucleic Acids Res 36, D919-D922 (2008).
2. Huang, C. et al. Systems pharmacology in drug discovery and therapeutic insight for herbal medicines. Brief Bioinform 15, 710-733 (2014).
3. Zheng, C. et al. System-level multi-target drug discovery from natural products with applications to cardiovascular diseases. Mol Divers 18, 621-635 (2014).
4. Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3, 711-716 (2004).
5. Yamanishi, Y., Kotera, M., Kanehisa, M. & Goto, S. Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework. Bioinformatics 26, i246-i254 (2010).
6. Takarabe, M., Kotera, M., Nishimura, Y., Goto, S. & Yamanishi, Y. Drug target prediction using adverse event report systems: a pharmacogenomic approach. Bioinformatics 28, i611-i618 (2012).
7. Mei, J.-P., Kwoh, C.-K., Yang, P., Li, X.-L. & Zheng, J. Drug-target interaction prediction by learning from local information and neighbors. Bioinformatics 29, 238-245 (2013).
8. Kuruvilla, F. G., Shamji, A. F., Sternson, S. M., Hergenrother, P. J. & Schreiber, S. L. Dissecting glucose signalling with diversityoriented synthesis and small-molecule microarrays. Nature 416, 653-657 (2002).
9. Haggarty, S. J., Koeller, K. M., Wong, J. C., Butcher, R. A. & Schreiber, S. L. Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays. Chem Biol 10, 383-396 (2003).
10. Stewart, L., Clark, R. & Behnke, C. High-throughput crystallization and structure determination in drug discovery. Drug Discov Today 7, 187-196 (2002).
11. Yamanishi, Y. et al. DINIES: drug-target interaction network inference engine based on supervised analysis. Nucleic Acids Res 42, W39-W45 (2014).
12. Cheng, A. C. et al. Structure-based maximal affinity model predicts small-molecule druggability. Nat Biotechnol 25, 71-75 (2007).
13. Fan, Y.-N., Xiao, X., Min, J.-L. & Chou, K.-C. iNR-Drug: Predicting the interaction of drugs with nuclear receptors in cellular networking. Int J Mol Sci 15, 4915-4937 (2014).
14. Yu, H. et al. A systematic prediction of multiple drug-target interactions from chemical, genomic, and pharmacological data. PLoS One 7, e37608 (2012).
15. Keiser, M. J. et al. Relating protein pharmacology by ligand chemistry. Nat Biotechnol 25, 197-206 (2007).
16. Wang, Y.-H., Li, Y., Yang, S.-L. & Yang, L. Classification of substrates and inhibitors of P-glycoprotein using unsupervised machine learning approach. J Chem Inf Model 45, 750-757 (2005).
17. Liu, T., Lin, Y., Wen, X., Jorissen, R. N. & Gilson, M. K. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res 35, D198-D201 (2007).
18. Law, V. et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res 42, D1091-D1097 (2014).
19. Berman, H., Henrick, K., Nakamura, H. & Markley, J. L. The worldwide Protein Data Bank (wwPDB): ensuring a single, uniform archive of PDB data. Nucleic Acids Res 35, D301-D303 (2007).
20. Salvat, R. S., Parker, A. S., Choi, Y., Bailey-Kellogg, C. & Griswold, K. E. Mapping the pareto optimal design space for a functionally deimmunized biotherapeutic candidate. PLoS Comput Biol 11, e1003988 (2015).
21. Muszkat, M. et al. The common Arg389gly ADRB1 polymorphism affects heart rate response to the ultra-short-acting β 1 adrenergic receptor antagonist esmolol in healthy individuals. Pharmacogenet Genom 23, 25-28 (2013).